Cited by 940Cancer Immunotherapy and BiomarkersT-cell and B-cell ImmunologyImmunotherapy and Immune Responses

The DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index.

CTLA-4: new insights into its biological function and use in tumor immunotherapy

Egen, Jackson G., Kuhns, Michael S., Allison, James P.·2002·Nature Immunology

Open this paper in CoChat — free account

Abstract

The discovery of multiple costimulatory cell surface molecules that influence the course of T cell activation has increased our appreciation of the complexity of the T cell response. It remains clear, however, that CD28 and cytotoxic T lymphocyte antigen 4 (CTLA-4) are the critical costimulatory receptors that determine the early outcome of stimulation through the T cell antigen receptor (TCR). Details of how the T cell integrates TCR stimulation with the costimulatory signals of CD28 and the inhibitory signals of CTLA-4 remain to be established, but unique features of the cell biology of CTLA-4 provide important insights into its function. We summarize here recent findings that suggest a previously unrecognized role for CTLA-4 in the regulation of T cell responses. We also describe preclinical and clinical results that indicate manipulation of CTLA-4 has considerable promise as a strategy for the immunotherapy of cancer.

Integrity signals

Registry

Crossref · 10.1038/ni0702-611

Cites

93 of 93 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Self-citation
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.
Dranoff, G., Jaffee, E. M., Lazenby, A., Golumbek, P. T., Levitsky, H., Brose, K., Jackson, V., Hamada, H., Pardoll, D. M., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,820
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
Krummel, M. F., & Allison, J. P. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.2.459 · Cited by 2,245
Self-citation
Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4
Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233
CTLA-4 can function as a negative regulator of T cell activation
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222
Cytotoxic T Lymphocyte–Associated Antigen 4 Plays an Essential Role in the Function of Cd25+Cd4+ Regulatory Cells That Control Intestinal Inflammation
Read, S., Malmström, V., & Powrie, F. M. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,206
B7/CD28 Costimulation Is Essential for the Homeostasis of the CD4+CD25+ Immunoregulatory T Cells that Control Autoimmune Diabetes
Salomon, B. L., Lenschow, D. J., Rhee, L., Ashourian, N., Singh, B., Sharpe, A. H., & Bluestone, J. A. (2000) · Immunity · doi:10.1016/s1074-7613(00)80195-8 · Cited by 2,058
The B7–CD28 superfamily
Sharpe, A. H., & Freeman, G. J. (2002) · Nature reviews. Immunology · doi:10.1038/nri727 · Cited by 1,759

Show all 93 references

Sorted by citations

Items 201–300 of 940

A dynamic view of the immunological synapse
Dustin, M. L. (2005) · Seminars in Immunology · doi:10.1016/j.smim.2005.09.002 · Cited by 112
Cutting Edge: CTLA-4–B7 Interaction Suppresses Th17 Cell Differentiation
Ying, H., Yang, L., Qiao, G., Li, Z., Zhang, L., Yin, F., Xie, D., & Zhang, J. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903369 · Cited by 115
Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions
Pansy, K., Uhl, B., Krstić, J., Szmyra, M., Fechter, K., Santiso, A., Thüminger, L., Greinix, H., Kargl, J., Prochazka, K. T., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413311 · Cited by 113
Unravelling the genetic complexity of autoimmune thyroid disease: HLA, CTLA-4 and beyond
Simmonds, M. J., & Gough, S. C. L. (2004) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2004.02424.x · Cited by 109
Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients
Wistuba-Hamprecht, K., Martens, A., Heubach, F., Romano, E., Geukes Foppen, M., Yuan, J., Postow, M., Wong, P., Mallardo, D., Schilling, B., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.12.011 · Cited by 108
CD152 (CTLA-4) Determines the Unequal Resistance of Th1 and Th2 Cells against Activation-induced Cell Death by a Mechanism Requiring PI3 Kinase Function
Pandiyan, P., Quandt, D., Soezeri, O., Radbruch, A., Schulze‐Osthoff, K., & Brunner-Weinzierl, M. C. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031058 · Cited by 108
Genetic insights into disease mechanisms of autoimmunity
Simmonds, M. J., & Gough, S. C. L. (2005) · British Medical Bulletin · doi:10.1093/bmb/ldh032 · Cited by 109
The promise of 4‐1BB (CD137)‐mediated immunomodulation and the immunotherapy of cancer
Lynch, D. H. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00621.x · Cited by 107
COEXPEDIA: exploring biomedical hypotheses via co-expressions associated with medical subject headings (MeSH)
Yang, S., Kim, C. Y., Hwang, S., Kim, E., Kim, H., Shim, H., & Lee, I. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw868 · Cited by 105
Functional Plasticity of Dendritic Cell Subsets as Mediated by CD40 Versus B7 Activation
Grohmann, U., Bianchi, R., Orabona, C., Fallarino, F., Vacca, C., Micheletti, A., Fioretti, M. C., & Puccetti, P. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.5.2581 · Cited by 105
Immunogenic anti-cancer chemotherapy as an emerging concept
Haynes, N. M., der Most, R. G. V., Lake, R., & Smyth, M. J. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.05.008 · Cited by 104
Control of Memory CD8+ T Cell Differentiation by CD80/CD86-CD28 Costimulation and Restoration by IL-2 during the Recall Response
Fuse, S., Zhang, W., & Usherwood, E. J. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.2.1148 · Cited by 104
HLA, CTLA-4 and PTPN22: the shared genetic master-key to autoimmunity?
Brand, O. J., Gough, S. C. L., & Heward, J. M. (2005) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399405009981 · Cited by 107
Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor
Curti, B. D., Koguchi, Y., Leidner, R. S., Rolig, A. S., Sturgill, E. R., Sun, Z., Wu, Y., Rajamanickam, V., Bernard, B. M., Hilgart-Martiszus, I., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002371 · Cited by 104
The impact of radiation therapy on the antitumor immunity: Local effects and systemic consequences
Lumniczky, K., & Sáfrány, G. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.08.024 · Cited by 103
Therapeutic Cancer Vaccines
Schlom, J., Hodge, J. W., Palena, C., Tsang, K.-Y., Jochéms, C., Greiner, J. W., Farsaci, B., Madan, R. A., Heery, C. R., & Gulley, J. L. (2014) · Advances in cancer research · doi:10.1016/b978-0-12-800249-0.00002-0 · Cited by 103
Invariant Natural Killer T Cells Regulate Breast Cancer Response to Radiation and CTLA-4 Blockade
Pilones, K. A., Kawashima, N., Yang, A. M., Babb, J. S., Formenti, S. C., & Demaria, S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1277 · Cited by 102
CD28 Co-Stimulation Down Regulates Th17 Development
Bouguermouh, S., Fortin, G., Baba, N., Rubio, M., & Sarfati, M. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005087 · Cited by 104
Polymeric microparticles for sustained and local delivery of antiCD40 and antiCTLA-4 in immunotherapy of cancer
Rahimian, S., Fransen, M. F., Kleinovink, J. W., Amidi, M., OSSENDORP, F. A., & Hennink, W. E. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.04.043 · Cited by 100
Immune Privilege as an Intrinsic CNS Property: Astrocytes Protect the CNS against T-Cell-Mediated Neuroinflammation
Gimsa, U., Mitchison, N. A., & Brunner-Weinzierl, M. C. (2013) · Mediators of Inflammation · doi:10.1155/2013/320519 · Cited by 107
Peptide-Specific CD8 T Regulatory Cells Use IFN-γ to Elaborate TGF-β-Based Suppression
Myers, L. M., Croft, M., Kwon, B. S., Mittler, R. S., & Vella, A. T. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.12.7625 · Cited by 100
VSIG4 expression on macrophages facilitates lung cancer development
Liao, Y., Guo, S. J., Chen, Y., Cao, D., Xu, H., Yang, C., Fei, L., Ni, B., & Ruan, Z. (2014) · Laboratory Investigation · doi:10.1038/labinvest.2014.73 · Cited by 99
The regulation of lymphocyte activation by inhibitory receptors
Leibson, P. J. (2004) · Current Opinion in Immunology · doi:10.1016/j.coi.2004.03.006 · Cited by 100
Attenuated T Cell Responses to a High-Potency Ligand In Vivo
Corse, E., Gottschalk, R. A., Krogsgaard, M., & Allison, J. P. (2010) · PLoS Biology · doi:10.1371/journal.pbio.1000481 · Cited by 98
Self-citation
Are medical and nonmedical uses of large-scale genomic markers conflating genetics and 'race'?
Rotimi, C. N. (2004) · Nature Genetics · doi:10.1038/ng1439 · Cited by 95
“Early” Middle Stone Age Lithic Technology of the Kapthurin Formation (Kenya)
Tryon, C. A. (2006) · Current Anthropology · doi:10.1086/503066 · Cited by 95
Genetic studies of African populations: an overview on disease susceptibility and response to vaccines and therapeutics
Sirugo, G., Hennig, B. J., Adeyemo, A., Matimba, A., Newport, M. J., Ibrahim, M. E., Ryckman, K. K., Tacconelli, A., Mariani‐Costantini, R., Novelli, G., et al. (2008) · Human Genetics · doi:10.1007/s00439-008-0511-y · Cited by 96
The role of the immune system in non-small cell lung carcinoma and potential for therapeutic intervention.
Domagala-Kulawik, J. J. (2015) · PubMed Central · doi:10.3978/j.issn.2218-6751.2015.01.11 · Cited by 94
Universes Collide: Combining Immunotherapy with Targeted Therapy for Cancer
Wargo, J. A., Cooper, Z. A., & Flaherty, K. T. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0477 · Cited by 94
The complex role of B7 molecules in tumor immunology
Seliger, B., Marincola, F. M., Ferrone, S., & Abken, H. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.09.010 · Cited by 93
Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression
Whiteside, T. L. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2010.482207 · Cited by 92
Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors.
Kleponis, J., Skelton, R. A., & Zheng, L. (2015) · Europe PMC (PubMed Central) · doi:10.7497/j.issn.2095-3941.2015.0046 · Cited by 91
The targeting of immunosuppressive mechanisms in hematological malignancies
Andersen, M. H. (2014) · Leukemia · doi:10.1038/leu.2014.108 · Cited by 91
Combination of Tumor Site–Located CTL-Associated Antigen-4 Blockade and Systemic Regulatory T-Cell Depletion Induces Tumor-Destructive Immune Responses
Tuve, S., Chen, B., Liu, Y., Cheng, T., Touré, P. S., Sow, P. S., Feng, Q., Kiviat, N., Strauss, R., Ni, S., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4296 · Cited by 92
Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma
Ivashko, I. N., & Kolesar, J. (2016) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp140768 · Cited by 95
Deciphering T-cell exhaustion in the tumor microenvironment: paving the way for innovative solid tumor therapies
Nair, R., Somasundaram, V., Kuriakose, A., Krishn, S. R., Raben, D., Salazar, R. L., & Nair, P. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1548234 · Cited by 100
Regulators of CD8+ T cell exhaustion
Sun, Q., & Dong, C. (2025) · Nature reviews. Immunology · doi:10.1038/s41577-025-01221-x · Cited by 91
Pancreatic Cancer Signaling Pathways, Genetic Alterations, and Tumor Microenvironment: The Barriers Affecting the Method of Treatment
Javadrashid, D., Baghbanzadeh, A., Derakhshani, A., Leone, P., Silvestris, N., Racanelli, V., Solimando, A. G., & Baradaran, B. (2021) · Biomedicines · doi:10.3390/biomedicines9040373 · Cited by 90
Unmasking immunosurveillance against a syngeneic colon cancer by elimination of CD4+ NKT regulatory cells and IL-13
Park, J. M., Terabe, M., van den Broeke, L. T., Donaldson, D. D., & Berzofsky, J. A. (2004) · International Journal of Cancer · doi:10.1002/ijc.20669 · Cited by 88
Clinically feasible approaches to potentiating cancer cell-based immunotherapies
Seledtsov, V. I., Гончаров, А. Г., & Seledtsova, G. V. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1009814 · Cited by 87
The inhibitory leukocyte-associated Ig-like receptor-1 (LAIR-1) is expressed at high levels by human naive T cells and inhibits TCR mediated activation
Maasho, K., Masilamani, M., Valas, R. B., Basu, S., Coligan, J. E., & Borrego, F. (2005) · Molecular Immunology · doi:10.1016/j.molimm.2005.01.004 · Cited by 86
Induction of Autoantigen-Specific Th2 and Tr1 Regulatory T Cells and Modulation of Autoimmune Diabetes
Chen, C., Lee, W.-H., Yun, P., Snow, P. M., & Liu, C. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.2.733 · Cited by 86
CTLA-4 blockade: therapeutic potential in cancer treatments
Tarhini, A. A. (2010) · OncoTargets and Therapy · doi:10.2147/ott.s4833 · Cited by 84
Combining PARP Inhibition, Radiation, and Immunotherapy: A Possible Strategy to Improve the Treatment of Cancer?
Césaire, M., Thariat, J., Candéias, S. M., Stefan, D., Saintigny, Y., & Chevalier, F. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123793 · Cited by 85
Immune checkpoint inhibitors-induced autoimmunity: The impact of gender
Triggianese, P., Novelli, L., Galdiero, M. R., Chimenti, M. S., Conigliaro, P., Perricone, R., Perricone, C., & Gerli, R. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102590 · Cited by 85
Vaccination for Treatment and Prevention of Cancer in Animal Models
Cavallo, F., Offringa, R., van der Burg, S. H., Forni, G., & Melief, C. J. M. (2006) · Advances in immunology · doi:10.1016/s0065-2776(06)90005-4 · Cited by 83
CTLA4 blockade reduces immature myeloid cells in head and neck squamous cell carcinoma
Yu, G., Bu, L., Zhao, Y., Mao, L., Deng, W., Wu, T., Zhang, W., & Sun, Z. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1151594 · Cited by 83
Combination Therapy of Established Tumors by Antibodies Targeting Immune Activating and Suppressing Molecules
Takeda, K., Kojima, Y., Uno, T., Hayakawa, Y., Teng, M. W. L., Yoshizawa, H., Yagita∥, H., Gejyo, F., Okumura, K., & Smyth, M. J. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903033 · Cited by 82
CD8+ T Cells Regulate Bone Tumor Burden Independent of Osteoclast Resorption
Zhang, K., Kim, S., Cremasco, V., Hirbe, A. C., Novack, D. V., Weilbaecher, K. N., & Faccio, R. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3922 · Cited by 82
Cycloxygenase-2 Inhibition Augments the Efficacy of a Cancer Vaccine
Haas, A. R., Sun, J., Vachani, A., Wallace, A. F., Silverberg, M. B., Kapoor, V., & Albelda, S. Μ. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1178 · Cited by 82
Sex estimation from the long bones of modern South Africans
Krüger, G. C., L’Abbé, E. N., & Stull, K. E. (2016) · International Journal of Legal Medicine · doi:10.1007/s00414-016-1488-z · Cited by 81
Immunotherapeutic approaches to ovarian cancer treatment
Chester, C., Dorigo, O., Berek, J. S., & Kohrt, H. E. K. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0051-7 · Cited by 84
Complimentary mechanisms of dual checkpoint blockade expand unique T-cell repertoires and activate adaptive anti-tumor immunity in triple-negative breast tumors
Crosby, E. J., Wei, J.-P., Yang, X. Y., Lei, G., Wang, T., Liu, C.-X., Agarwal, P., Korman, A. J., Morse, M. A., Gouin, K. H., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1421891 · Cited by 81
CTLA-4 Blockade Enhances the Therapeutic Effect of an Attenuated Poxvirus Vaccine Targeting p53 in an Established Murine Tumor Model
Espenschied, J. R., Lamont, J., Longmate, J., Pendas, S., Wang, Z., Diamond, D. J., & Ellenhorn, J. D. I. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.6.3401 · Cited by 79
B‐cell activation in patients with irritable bowel syndrome (IBS)
öhman, L., Lindmark, A. ‐., Isaksson, S., Posserud, I., Strid, H., Sjövall, H., & Simrén, M. (2009) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2009.01272.x · Cited by 78
Immune-Related Adverse Events: Pneumonitis
Zhong, L., Altan, M., Shannon, V. R., & Sheshadri, A. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-41008-7_13 · Cited by 80
Conjunctival melanoma: New insights in tumour genetics and immunology, leading to new therapeutic options
Brouwer, N. J., Verdijk, R. M., Heegaard, S., Marinkovic, M., Esmaeli, B., & Jager, M. J. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.100971 · Cited by 81
Biomarkers of response to immune checkpoint blockade in cancer treatment
Fujii, T., Naing, A., Rolfo, C. D., & Hajjar, J. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.07.010 · Cited by 77
Melanoma brain metastasis: overview of current management and emerging targeted therapies
Fonkem, E., Uhlmann, E. J., Floyd, S., Mahadevan, A., Kasper, E. M., Eton, O. E., & Wong, E. T. (2012) · Expert Review of Neurotherapeutics · doi:10.1586/ern.12.111 · Cited by 75
Ipilimumab-induced Perforating Colitis
Mitchell, K. A., Kluger, H. M., Sznol, M., & Hartman, D. J. (2013) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e31828f1d51 · Cited by 74
CD4+CD25+ Regulatory T Lymphocytes in Malignant Pleural Effusion
Chen, Y., Shi, H., Qin, X., Mo, W., Liang, X.-D., Huang, Z.-X., Yang, H., & Wu, C. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200504-588oc · Cited by 74
Cancer vaccines 2004 opening address: the molecular and cellular basis of cancer immunosurveillance and immunoediting.
Todorova, K. O., Ignatova, I., Tchakarov, S., Altankova, I., Zoubak, S., Kyurkchiev, S., & Mincheff, M. S. (2005) · PubMed · Cited by 74
Mechanisms of immune response regulation in lung cancer.
Domagala-Kulawik, J. J., Osińska, I., & Hoser, G. (2014) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2013.11.03 · Cited by 73
CD80 and CD86 Control Antiviral CD8 + T-Cell Function and Immune Surveillance of Murine Gammaherpesvirus 68
Fuse, S., Obar, J. J., Bellfy, S. C., Leung, E. K., Zhang, W., & Usherwood, E. J. (2006) · Journal of Virology · doi:10.1128/jvi.00422-06 · Cited by 73
Adjuvant Effect of Toll-Like Receptor 9 Activation on Cancer Immunotherapy Using Checkpoint Blockade
Chuang, Y.-C., Tseng, J., Huang, L.-R., Huang, C., Huang, C. F., & Chuang, T. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01075 · Cited by 74
Astrocytes protect the CNS: antigen-specific T helper cell responses are inhibited by astrocyte-induced upregulation of CTLA-4 (CD152)
Gimsa, U., �ren, A., Pandiyan, P., Teichmann, D., Bechmann, I., Nitsch, R., & Brunner-Weinzierl, M. C. (2004) · Journal of Molecular Medicine · doi:10.1007/s00109-004-0531-6 · Cited by 73
Immunotherapy by Immune Checkpoint Inhibitors and Nuclear Medicine Imaging: Current and Future Applications
Decazes, P., & Bohn, P. (2020) · Cancers · doi:10.3390/cancers12020371 · Cited by 74
Cancer/testis antigens: from serology to mRNA cancer vaccine
Fan, C., Qu, H., Wang, X., Sobhani, N., Wang, L., Liu, S., Xiong, W., Zeng, Z., & Li, Y. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.04.016 · Cited by 72
Curcumin as an Adjuvant to Cancer Immunotherapy
Paul, S., & Sa, G. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.675923 · Cited by 74
Overcoming immune resistance by sequential prodrug nanovesicles for promoting chemoimmunotherapy of cancer
Zhou, F., Gao, J., Xu, Z., Li, T., Gao, A., Sun, F. Z., Wang, F., Wang, W., Geng, Y., Zhang, F., et al. (2020) · Nano Today · doi:10.1016/j.nantod.2020.101025 · Cited by 71
PLGA-nanoparticle mediated delivery of anti-OX40 monoclonal antibody enhances anti-tumor cytotoxic T cell responses
Chen, M., Ouyang, H., Zhou, S., Li, J., & Ye, Y. (2014) · Cellular Immunology · doi:10.1016/j.cellimm.2014.01.003 · Cited by 71
Induction of tumor NK-cell immunity by anti-CD69 antibody therapy
Esplugues, E., Vega‐Ramos, J., Cartoixà, D., Vázquez, B. N., Salaet, I., Engel, P., & Lauzurica, P. (2005) · Blood · doi:10.1182/blood-2004-10-3854 · Cited by 73
Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti–PD-1 Refractory Melanoma
Haymaker, C., Johnson, D. H., Murthy, R., Bentebibel, S.-E., Uemura, M. I., Hudgens, C. W., Safa, H., James, M. L., Andtbacka, R. H. I., Johnson, D. B., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1546 · Cited by 70
Using an Alzheimer Disease Polygenic Risk Score to Predict Memory Decline in Black and White Americans Over 14 Years of Follow-up
Marden, J. R., Mayeda, E. R., Walter, S., Vivot, A., Tchetgen, E. J. T., Kawachi, I. I., & Glymour, M. M. (2016) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000137 · Cited by 73
Radiation therapy and immunotherapy: Implications for a combined cancer treatment
Lévy, A., Chargari, C., Cheminant, M., Simon‐Tillaux, N., Bourgier, C., & Deutsch, É. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.09.001 · Cited by 72
Effects of microenvironment in osteosarcoma on chemoresistance and the promise of immunotherapy as an osteosarcoma therapeutic modality
Yu, L., Zhang, J., & Li, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.871076 · Cited by 68
Belatacept: from rational design to clinical application
Wekerle, T., & Grinyo, J. M. (2011) · Transplant International · doi:10.1111/j.1432-2277.2011.01386.x · Cited by 70
CTLA-4 gene polymorphism +49 A/G contributes to genetic susceptibility to two infection-related cancers—hepatocellular carcinoma and cervical cancer
Hu, L., Liu, J., Chen, X., Zhang, Y., Liu, L., Zhu, J., Chen, J., Shen, H., Qiang, F., & Hu, Z. (2010) · Human Immunology · doi:10.1016/j.humimm.2010.05.023 · Cited by 68
Genetic and epigenetic factors in autoimmune reactions toward cytochrome P4502E1 in alcoholic liver disease
Vidali, M., Stewart, S. F., Rolla, R., Daly, A. K., Chen, Y., Mottaran, E., Jones, D. E. J., Leathart, J. B. S., Day, C. P., & Albano, E. (2003) · Hepatology · doi:10.1053/jhep.2003.50049 · Cited by 68
Block and tackle: CTLA4Ig takes on lupus
Davidson, A., Diamond, B., Wofsy, D., & Daikh, D. (2005) · Lupus · doi:10.1191/0961203305lu2136oa · Cited by 68
Cytochrome P450 pharmacogenetics in African populations
Alessandrini, M., Asfaha, S. M., Dodgen, T. M., Warnich, L., & Pepper, M. S. (2013) · Drug Metabolism Reviews · doi:10.3109/03602532.2013.783062 · Cited by 67
Combination of CTL-associated Antigen-4 Blockade and Depletion of CD25+Regulatory T Cells Enhance Tumour Immunity of Dendritic Cell-based Vaccine in a Mouse Model of Colon Cancer
Saha, A., & Chatterjee, S. K. (2009) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2009.02355.x · Cited by 67
Enhancing efficacy of therapeutic vaccinations by combination with other modalities
Gulley, J. L., Madan, R. A., & Arlen, P. M. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.04.091 · Cited by 68
The role of CTLA-4 and PD-1 in anti-tumor immune response and their potential efficacy against osteosarcoma
Wang, S., Li, H., Li, B., Xie, T., Zhu, T., Sun, L., Ren, H., & Ye, Z. (2016) · International Immunopharmacology · doi:10.1016/j.intimp.2016.05.016 · Cited by 67
From immune checkpoints to vaccines: The past, present and future of cancer immunotherapy
Osipov, A., Murphy, A. G., & Zheng, L. (2019) · Advances in cancer research · doi:10.1016/bs.acr.2019.03.002 · Cited by 69
Association of CTLA‐4 gene polymorphism with oral squamous cell carcinoma
Wong, Y. K., Chang, K., Cheng, C., & Liu, C. ‐. (2005) · Journal of Oral Pathology and Medicine · doi:10.1111/j.1600-0714.2005.00377.x · Cited by 67
Inhibition of T cell activation and autoimmune diabetes using a B cell surface-linked CTLA-4 agonist
Fife, B. T. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27856 · Cited by 68
Immune checkpoint blockade and its combination therapy with small-molecule inhibitors for cancer treatment
Wang, M., Liu, Y., Cheng, Y., Wei, Y., & Wei, X. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.12.002 · Cited by 66
Immunotherapy targeting different immune compartments in combination with radiation therapy induces regression of resistant tumors
Rudqvist, N.-P., Charpentier, M., Lhuillier, C., Wennerberg, E., Spada, S., Sheridan, C. K., Zhou, X. K., Zhang, T., Formenti, S. C., Sims, J. S., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40844-3 · Cited by 68
Altering regulatory T cell function in cancer immunotherapy: a novel means to boost the efficacy of cancer vaccines
Rüter, J. (2009) · Frontiers in bioscience · doi:10.2741/3338 · Cited by 66
Radiotherapy Enhances Antitumor Effect of Anti-CD137 Therapy in a Mouse Glioma Model
Newcomb, E. W., Lukyanov, Y., Kawashima, N., Alonso‐Basanta, M., Wang, S., Liu, M., Jure‐Kunkel, M., Zagzag, D., Demaria, S., & Formenti, S. C. (2010) · Radiation Research · doi:10.1667/rr1904.1 · Cited by 68
Intestinal microbiota: a novel perspective in colorectal cancer biotherapeutics
Ding, C., Tang, W., Fan, X., & Wu, G. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s170626 · Cited by 68
Immunoregulatory and Susceptibility Genes in Thyroid and Polyglandular Autoimmunity
Dittmar, M., & Kahaly, G. J. (2005) · Thyroid · doi:10.1089/thy.2005.15.239 · Cited by 66
CD25 regulatory T cells determine secondary but not primary remission in EAE: Impact on long-term disease progression
Quandt, D., Hoff, H., Gimsa, U., Burmester, G. R., & Brunner-Weinzierl, M. C. (2005) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2005.11.003 · Cited by 67
Recent advances and future of immunotherapy for glioblastoma
Kamran, N., Calinescu, A., Candolfi, M., Chandran, M., Mineharu, Y., Asad, A. S., Koschmann, C. J., Núñez, F. J., Lowenstein, P. R., & Castro, M. G. (2016) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2016.1212012 · Cited by 67
Cancer chemoprevention: signaling pathways and strategic approaches
Ren, J., Yan, G., Yang, L., Kong, L., Guan, Y., Sun, H., Liu, C., Liu, L., Han, Y., & Wang, X. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02167-1 · Cited by 67
Immune mechanisms in alcoholic liver disease
Albano, E., & Vidali, M. (2009) · Genes & Nutrition · doi:10.1007/s12263-009-0151-4 · Cited by 63
ICOS Regulates the Generation and Function of Human CD4+ Treg in a CTLA-4 Dependent Manner
Zheng, J. H., Chan, P., Liu, Y., Qin, G., Xiang, Z., Lam, K.-T., Lewis, D. B., Lau, Y., & Tu, W. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082203 · Cited by 63
Immune checkpoints in tumor microenvironment and their relevance to the development of cancer stem cells
Khosravi, N., Mokhtarzadeh, A., Baghbanzadeh, A., Hajiasgharzadeh, K., Khaze, V., Hemmat, N., Safarzadeh, E., & Baradaran, B. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118005 · Cited by 62
Embryonic Stem Cells: Overcoming the Immunological Barriers to Cell Replacement Therapy
Lui, K. O., Waldmann, H., & Fairchild, P. J. (2009) · Current Stem Cell Research & Therapy · doi:10.2174/157488809787169093 · Cited by 62

Authors: Egen, J. G., Kuhns, M. S., & Allison, J. P.
Affiliations: Howard Hughes Medical Institute (US)
Corresponding author: Allison, James P.
ORCID: Egen, Jackson G.
Kuhns, Michael S.
Allison, James P.
Venue: Nature Immunology
Publisher: Springer Science and Business Media LLC
Published: 2002-07
Volume: 3
Issue: 7
Pages: 611-618
ISSN: 1529-2908 (ISSN-L)
1529-2916
DOI: 10.1038/ni0702-611
OpenAlex: W2140460887
Cited by: 940
References: 93
Citations by year: 2026: 10 · 2025: 15 · 2024: 30 · 2023: 34 · 2022: 45 · 2021: 50 · 2020: 43 · 2019: 33 · 2018: 27 · 2017: 36 · 2016: 28 · 2015: 32 · 2014: 31 · 2013: 38 · 2012: 25
FWCI: 5.88
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature Immunology (publishedVersion)
PubMed (publishedVersion)
Funders: Howard Hughes Medical Institute
National Institutes of Health
National Cancer Institute (CA40041, R01CA057986, CA57986)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords: CTLA-4, costimulatory receptors, CD28, T cell activation, T cell receptor signaling, T cell regulation, cancer immunotherapy, CTLA-4 blockade, immune checkpoint blockade
MeSH terms: Abatacept, Animals, Antigens, Differentiation, Cell Division, Colonic Neoplasms, Disease Models, Animal, Fibrosarcoma, Gene Expression Regulation, Humans, Immunotherapy, Lymphocyte Activation, Neoplasms, T-Lymphocytes, Antigens, CD, Immunoconjugates, Mice, CTLA-4 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

CTLA-4: new insights into its biological function and use in tumor immunotherapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks